Nidan Laboratories and Healthcare
- Market cap
- ₹ 17 Cr.
- P/E
- 10.2x
- P/B
- 0.25x
- 52-week range
- 11.5 – 24.9
- ROE
- 3%
- ROCE
- 6%
- Dividend yield
- 0%
- Debt / equity
- 0.16
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- NSE SME
About
Nidan Laboratories and Healthcare Limited is an India-based company. The Company is engaged in providing diagnostic services including pathology, radiology, cardiology, and neurology. Its laboratory tests offer a range of over 6000 clinical laboratory tests and profiles, which are used to provide diagnostic services for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease using technological advanced machines, prenatal screening, to screening for hormonal imbalance, nutritional deficiencies, and tracking lifestyle disorders. Its services include computed tomography (CT) scans, X-radiation (X-ray), pathology, cardio, magnetic resonance imaging (MRI), sonography, outpatient department (OPD) and others. Its lab tests include CT Lower Limb Arteriography And Venography, CT Whole Spine, CT Abdomen Angiography, CT Lumber Spine, CT Calcium Scoring, Dry Film D12, CT Extra Report and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Nidan Laboratories and Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)10.2 against a typical 21: cheaper than most peers (1st = cheapest).5th of 34
- Sales growth+0.6% against a typical +19.1% from a year earlier.27th of 31
- Share price, 3 months−1.1% against a typical −7.7%.10th of 33
- Size₹ 17.1 Cr. market value against a typical ₹ 83 Cr. (1st = largest).26th of 34
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil B(Issuer Not Cooperating) | Stable | 23 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 23 Apr 2026 | Reaffirmed | Crisil B(Issuer Not Cooperating) | — | CRISIL | ₹ 15 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 20 Aug 2026 | Other business matters | To consider other business matters inter alia to consider and approve convening of Annual General Meeting of the Company. |
| 25 May 2026 | Financial Results | To consider and approve the audited financial results for the period ended March 31, 2026 |
| 5 Feb 2026 | Other business matters | To consider other business matters |
| 10 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 31 Jul 2025 | Other business matters | Please be informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 31st July, 2025 inter-alia to consider and approve the convening of Annual General Meeting of the Company |
| 28 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 14 | 10 | 12 | 12 | 11 | 14 | 13 | 12 |
| Expenses | 10 | 9 | 9 | 8 | 9 | 8 | 12 | 11 | 10 |
| Operating Profit | 4 | 5 | 2 | 3 | 3 | 3 | 2 | 3 | 2 |
| OPM % | 27.6% | 36.6% | 16.1% | 28.3% | 25.2% | 24.7% | 17.6% | 19.4% | 18.5% |
| Other Income | 0 | 0 | 3 | 2 | −5 | 1 | 1 | 1 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 3 | 2 | 3 | −5 | 1 | 1 | 2 | 1 |
| Tax % | 61.2% | 23.5% | 31.3% | 26.2% | 3.6% | 22% | 34.8% | 24.6% | 87% |
| Net Profit | 1 | 2 | 1 | 2 | −5 | 1 | 1 | 1 | 0 |
| EPS in Rs | 0.62 | 1.67 | 0.88 | 1.38 | −3.71 | 0.79 | 0.63 | 1.03 | 0.05 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 5%
- 3 Years
- 2%
- TTM
- 4%
- 10 Years
- —
- 5 Years
- −5%
- 3 Years
- −19%
- TTM
- −8%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −25%
- TTM
- —
- 10 Years
- —
- 5 Years
- 3%
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Nidan Laboratories and Healthcare | ₹ 13.00 | ₹ 17 Cr. | 10.2x | 0.3x | 3% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Nitin Vitharao Thorve
- Chief Executive Officer
- Tejal Anil Jayakar
- Chief Financial Officer, Executive Director
- Varsha Maniar
- Compliance Officer, Company Secretary
- Edwin Francis Dabre
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.